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Abstract
Background: Although caffeine and glucocorticoids are frequently used to treat chronic lung disease in preterm
neonates, potential interactions are largely unknown. While anti-inflammatory effects of glucocorticoids are well
defined, their impact on airway remodeling is less characterized. Caffeine has been ascribed to positive effects on
airway inflammation as well as remodeling. Connective tissue growth factor (CTGF, CCN2) plays a key role in airway
remodeling and has been implicated in the pathogenesis of chronic lung diseases such as bronchopulmonary
dysplasia (BPD) in preterm infants. The current study addressed the impact of glucocorticoids on the regulation of
CTGF in the presence of caffeine using human lung epithelial and fibroblast cells.
Methods: The human airway epithelial cell line H441 and the fetal lung fibroblast strain IMR-90 were exposed to
different glucocorticoids (dexamethasone, budesonide, betamethasone, prednisolone, hydrocortisone) and caffeine.
mRNA and protein expression of CTGF, TGF-β1-3, and TNF-α were determined by means of quantitative real-time
PCR and immunoblotting. H441 cells were additionally treated with cAMP, the adenylyl cyclase activator forskolin,
and the selective phosphodiesterase (PDE)-4 inhibitor cilomilast to mimic caffeine-mediated PDE inhibition.
Results: Treatment with different glucocorticoids (1 μM) significantly increased CTGF mRNA levels in H441 (p < 0.0001)
and IMR-90 cells (p < 0.01). Upon simultaneous exposure to caffeine (10 mM), both glucocorticoid-induced mRNA and
protein expression were significantly reduced in IMR-90 cells (p < 0.0001). Of note, 24 h exposure to caffeine alone
significantly suppressed basal expression of CTGF mRNA and protein in IMR-90 cells. Caffeine-induced reduction of
CTGF mRNA expression seemed to be independent of cAMP levels, adenylyl cyclase activation, or PDE-4 inhibition.
While dexamethasone or caffeine treatment did not affect TGF-β1 mRNA in H441 cells, increased expression of TGF-β2
and TGF-β3 mRNA was detected upon exposure to dexamethasone or dexamethasone and caffeine, respectively.
Moreover, caffeine increased TNF-α mRNA in H441 cells (6.5 ± 2.2-fold, p < 0.05) which has been described as potent
inhibitor of CTGF expression.
Conclusions: In addition to well-known anti-inflammatory features, glucocorticoids may have adverse effects on
long-term remodeling by TGF-β1-independent induction of CTGF in lung cells. Simultaneous treatment with caffeine
may attenuate glucocorticoid-induced expression of CTGF, thereby promoting restoration of lung homeostasis.
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Background
Bronchopulmonary dysplasia (BPD) still represents a
major morbidity of preterm birth [1]. It has been deemed
an evolving process of chronic lung inflammation and
lung injury. Besides structural immaturity, pre- and post-
natal inflammation has been considered a principle mech-
anism in the initiation and aggravation of BPD. Various
adverse conditions, such as mechanical ventilation, may
amplify the inflammatory response and contribute to
severe lung injury [2–9]. The latter is characterized by im-
paired alveolarization and impaired vascular development
and culminates in severe airway remodeling with intersti-
tial and vascular fibrosis [10–13].
Connective tissue growth factor (CTGF), also known
as CCN family protein 2 (CCN2), is a matricellular protein,
that plays a key role in tissue development and remodeling,
interacting with a variety of other growth factors, such as
transforming growth factor (TGF)-β [14]. It has been
deemed a critical role in the pathogenesis of various forms
of adult pulmonary fibrosis and vascular disease [15, 16].
Both growth factors have been acknowledged as central
mediators promoting and accelerating fibrosis as well as
pathological airway remodeling [12, 17, 18]. In pulmonary
fibrosis, CTGF seems to be predominantly localized to pro-
liferating alveolar type II (ATII) cells and activated fibro-
blasts [19] and, thus, may play a central part as pro-fibrotic
mediator. In the neonatal lung, increased expression of
CTGF seems to be induced by mechanical ventilation and
hyperoxia, suggesting that CTGF may contribute to the
pathogenesis of BPD [20–22]. In addition, in neonatal
mice, a conditional overexpression of CTGF in ATII cells
was shown to induce lung fibrosis, resulting in a BPD-like
architecture [10]. These data may underline a key role
of CTGF in tissue fibrosis and airway remodeling,
both displaying important features of BPD. However,
underlying mechanisms of the transcriptional modula-
tion of CTGF, considered to be its predominant form
of regulation [23], may be complex and might depend
on the particular disease or the affected organ [24].
While TGF-β seems to induce CTGF gene expression
[23], tumor necrosis factor alpha (TNF-α), among
other factors, has been shown to reduce expression of
CTGF [25].
Besides, there is considerable evidence of an even
more complex interplay of CTGF and TGF-β [26].
CTGF seems to enhance the impact of TGF-β in the
context of pro-inflammation [27]. It may act as a co-
factor for TGF-β, but can also activate TGF-β in extra-
cellular matrix signaling [28]. In pro-inflammatory lung
injury, in concert with TGF-β, CTGF seems to trigger
the production of remodeling molecules in the extracel-
lular matrix [27]. Increased expression of both TGF-β1
and CTGF has been associated with severe forms of
BPD [6, 22, 29–32].
In preterm infants, the administration of glucocorti-
coids aiming at the attenuation of BPD has long been
subject to controversy [33, 34]. Glucocorticoids may be
used to accelerate weaning from respiratory support [35]
and to treat or prevent chronic inflammatory diseases
[36] as well as fibrotic lung disease [12]. However,
potential adverse effects on long-term airway remodeling
are a matter of ongoing debate [37, 38]. Effects of gluco-
corticoid administration on CTGF signaling, in particu-
lar, have not been sufficiently investigated, so far.
Potential adverse effects on the lung epithelium demand
further studies on the impact of glucocorticoids on
airway remodeling [12].
The methylxanthine caffeine is commonly used to
reduce apnea of prematurity [39, 40]. Of note, caffeine
treatment has been associated with reduced incidences
of BPD [41] and the prevention of hyperoxia-mediated
pulmonary inflammation and lung injury [42, 43].
Although caffeine has been demonstrated anti-inflam
matory [44] and antifibrotic effects [45, 46], its potential
impact on airway remodeling has not been investigated
in detail.
We recently demonstrated that caffeine is able to
antagonize TGF-β1 induced upregulation of CTGF on
the transcriptional and translational level [47] and that
gene expression-related additive and synergistic effects
exist for caffeine in combination with dexamethasone
[48, 49]. At higher concentrations, caffeine may act as
an unspecific inhibitor of PDEs increasing intracellular
levels of cAMP. At lower concentrations, predominantly
nonselective antagonism on adenosine receptors but also
roles in histone acetylation and deacetylation have been
reported [50–53].
It is of high relevance to better characterize potential
pro-fibrotic effects of glucocorticoids and caffeine in the
context of BPD and airway remodeling. Considering the
importance of CTGF for normal lung development and
pro-fibrotic processes independent of the underlying dis-
ease [14], thrown off regulatory balance in the preterm
lung during BPD, a modulation of CTGF expression
might be vitally important to counteract restricted lung
development caused by fibrotic processes and pathologic
airway remodeling. The current study addressed the im-
pact of glucocorticoids and caffeine, alone or in combin-
ation, on CTGF expression in different lung cells.
Methods
Reagents
Caffeine, dexamethasone, budesonide, betamethasone,
prednisolone, hydrocortisone, 8-Br-cyclic adenosine
monophosphate (cAMP), forskolin, cilomilast, and re-
combinant human TNF-α were purchased from Sigma-
Aldrich (St. Louis, CA).
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Cells
Human airway epithelial cells NCI-H441 (H441) and the
fetal lung fibroblast strain IMR-90 were purchased from
ATCC (LGC Standards, Teddington, UK) and cultured
as described, respectively, without sodium pyruvate and
nonessential amino acids in case for IMR-90 [48, 54].
Incubation was carried out at 37 °C in a humidified
atmosphere with 5% CO2. For stimulation assays with
glucocorticoids and caffeine, H441 and IMR-90 cells
were seeded on six well plates (Greiner, Frickenhausen,
Germany) until 80% confluence was reached and subse-
quently incubated with substances in growth medium as
indicated in a total volume of 1 mL until further pro-
cessing. Preliminary dose–response experiments using
concentrations of 100 μM, 1 mM, and 10 mM caffeine
revealed highest effects for 10 mM. Therefore the latter
concentration was used throughout all experiments.
Neutralization assay
To neutralize extracellular TNF-α, antibodies against
human TNF-α (clone 2C8; Abcam, Cambridge, United
Kingdom) were used in a concentration of 5 μg/mL.
RNA extraction and RT-PCR
For RNA extraction, cells were treated as indicated and
total RNA was isolated using NucleoSpin® RNA Kit
(Macherey-Nagel, Dueren, Germany) according to the
manufacturer’s protocol. For quantification of total RNA,
a Qubit® 2.0 Fluorometer (Thermo Fisher Scientific,
Waltham, MA) was used as recommended by the manu-
facturer. Total RNA was eluted in 60 μL nuclease-free
H2O (Sigma-Aldrich) and stored at −80 °C until reverse
transcription. For RT-PCR, 1 μg of total RNA was reverse
transcribed using High Capacity cDNA Reverse Transcrip-
tion Kit (Thermo Fisher Scientific) according to the man-
ufacturer’s instructions. First strand cDNA was diluted 1
to 10 with deionized, nuclease-free H2O (Sigma-Aldrich)
and stored at −20 °C upon analysis.
Quantitative real time RT-PCR (qPCR)
For quantitative detection of mRNA, 10 μL of diluted
first strand cDNA were analyzed in duplicates of 25 μL
reactions using 12.5 μL iTaq™ Universal SYBR® Green
Supermix (Bio-Rad Laboratories, Hercules, CA), 0.5 μL
deionized H2O, and 1 μL of a 10 μM solution of forward
and reverse primers (Sigma-Aldrich) as indicated in
table 1. PCRs were performed on an Applied Biosys-
tems® 7500 Real-Time PCR System (Thermo Fisher
Scientific) using a 2-step PCR protocol after an initial
denaturation at 95 °C for 10 min with 40 cycles of 95 °C
for 15 s and 60 °C for 1 min. A melt curve analysis was
performed at the end of every run to verify single PCR
products. Levels of mRNAs were normalized to those of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Mean fold changes in mRNA expression were calculated
by the ΔΔCT method by Livak and Schmittgen [55].
Immunoblotting
Immunoblotting was performed as previously described
[48]. Blots were probed with primary antibodies to
CTGF (clone L-20; Santa Cruz Biotechnology Inc., Santa
Cruz, CA), and β-actin (926–42212; LI-COR, Lincoln,
NE), followed by staining with corresponding IRDye®
secondary antibodies (LI-COR) for 1 h at RT. Specific
protein bands were visualized using an ODYSSEY®
Infrared Imaging System (LI-COR). Accumulated sig-
nals were quantified using Image Studio Lite v5.0.21
(LI-COR).
Statistical analysis
Results are given as means ± SD. Unless stated otherwise,
data were analyzed using one way ANOVA with Bonferro-
ni’s multiple comparison post hoc test. A p-value ≤ 0.05
Table 1 Primers for qPCR
Gene symbol Sequence accession # Orientation Sequence [5′ to 3′] Amplicon length [bp]
CTGF NM_001901.2 forward ACCCAACTATGATTAGAGCC 189
reverse TTGCCCTTCTTAATGTTCTC
GAPDH NM_002046.5 forward CCATGGAGAAGGCTGGGG 195
reverse CAAAGTTGTCATGGATGACC
TGFB1 NM_000660.5 forward AATTCCTGGCGATACCTC 192
reverse TAGTGAACCCGTTGATGTC
TGFB2 NM_001135599.2 forward AGATTTGCAGGTATTGATGG 106
reverse ATTAGCAGGAGATGTGGG
TGFB3 NM_003239.3 forward CAAAGGCGTGGACAATGAG 200
reverse ACACAGCAGTTCTCCTCC
TNF NM_000594.3 forward CAGCCTCTTCTCCTTCCT 188
reverse GGGTTTGCTACAACATGG
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was considered significant. All statistical analyses were
performed using Prism® version 6 (GraphPad Software,
San Diego, CA).
Results
Effect of glucocorticoids and caffeine on CTGF mRNA
expression in H441 and IMR-90 cells
To investigate a potential impact of glucocorticoids and/
or caffeine on expression of CTGF mRNA, we treated
H441 and IMR-90 cells with various glucocorticoids
alone or in combination with caffeine. We observed a
significant induction of CTGF mRNA for dexametha-
sone, budesonide, betamethasone, prednisolone, and
hydrocortisone in H441 and IMR-90 cells. Highest levels
of CTGF mRNA induction were reached in H441 cells
(8.4 to 12.9-fold, p < 0.0001 for all glucocorticoids;
Fig. 1a) followed by those in IMR-90 cells (1.4 to 1.7-
fold, p = 0.0015 for hydrocortisone and p < 0.0001 for all
other glucocorticoids; Fig. 1b). In contrast, exposure of
both cell lines to caffeine did not induce CTGF mRNA
expression, but significantly reduced basal CTGF mRNA
levels in IMR-90 cells (p = 0.0221; Fig. 1b). For H441
cells, these effects were not statistically significant
(Fig. 1a). Of note, simultaneous exposure of lung cells to
glucocorticoids and caffeine significantly prevented
glucocorticoid-induced CTGF expression in H441 as
well as in IMR-90 cells (p < 0.0001 for all glucocorticoids
in combination with caffeine; Figs. 1a and b).
Effect of glucocorticoids and caffeine on CTGF protein
expression in IMR-90 cells
As far as protein expression was concerned, CTGF was
undetectable in H441 cells for every condition at 24 h in-
cubation (data not shown). In IMR-90 cells, a significant
induction of CTGF was detected after a 24 h treatment
with dexamethasone (1.3 ± 0.3-fold, p = 0.0289; Fig. 2).
Fig. 1 Reduction of glucocorticoid-induced CTGF mRNA expression in H441 and IMR-90 cells by caffeine. H441 and IMR-90 cells were treated with
1 μM of the indicated glucocorticoids and/or 10 mM caffeine for 24 h. qPCR against CTGF mRNA was performed as described in Methods. CTGF
mRNA levels of H441 cells (a) and IMR-90 cells (b) were normalized to GAPDH, and fold differences compared to untreated cells were calculated.
Means + SD of n ≥ 3 independent experiments are shown. ## p < 0.01, and ### p < 0.001 compared to untreated controls; *p < 0.05 and
***p < 0.001 compared to cells treated with the corresponding glucocorticoid
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CTGF protein levels were significantly lower in IMR-90
cells treated with caffeine alone or in combination
with dexamethasone in comparison to untreated cells
(p = 0.009 and p = 0.0001, respectively) as well as in
comparison to cells treated with dexamethasone alone
(p < 0.0001 for both conditions; Fig. 2).
The given results indicate that CTGF expression is in-
duced by glucocorticoids on a transcriptional and trans-
lational level in lung epithelial and fibroblast cells and
that this induction may be prevented by simultaneous
exposure to caffeine.
Impact of dexamethasone and caffeine on TGF-β1-3
mRNA expression in H441 cells
To identify underlying molecular mechanisms of
caffeine-induced suppression of CTGF, we analyzed
mRNA expression of TGF-β1-3 in H441 cells following
treatment with either dexamethasone or caffeine or a
combination of both. Neither dexamethasone nor
caffeine alone, nor a combination of both had any effect
on the expression of TGF-β1 mRNA (Fig. 3a). TGF-β2
mRNA was slightly upregulated by dexamethasone
(1.5 ± 0.3-fold, p = 0.0366; Fig. 3b), while there was no
induction observable if caffeine was present. In contrast,
both dexamethasone and caffeine significantly induced
TGF-β3 mRNA either alone (1.8 ± 0.3-fold, p = 0.0066
and 2.4 ± 0.7-fold, p < 0.0001, respectively) or in com-
bination (2.4 ± 0.6-fold, p = 0.0004; Fig. 3c). Induction
of TGF-β3 mRNA was significantly higher in caffeine-
treated cells in comparison to dexamethasone-treated cells
(1.4 ± 0.4-fold, p = 0.0373; Fig. 3c). The given results may
demonstrate that dexamethasone does not induce TGF-β1
but slightly induces TGF-β2 mRNA expression in H441
cells and that the inhibitory effects of caffeine could be, at
least in part, mediated via a reduction of TGF-β2 but not
TGF-β1 mRNA.
Impact of cAMP, forskolin, cilomilast, and ruthenium red
on CTGF mRNA expression in H441 cells
To reveal if a caffeine-induced inhibition of PDEs [52]
was responsible for the observed inhibitory effect of caf-
feine, we treated H441 cells with dexamethasone and/or
cAMP, the adenylyl cyclase activator forskolin, and the
selective PDE-4 inhibitor cilomilast and subsequently
measured CTGF mRNA levels. Unexpectedly, treatment
of H441 cells with cAMP significantly increased CTGF
mRNA expression (7.2 ± 2.1-fold, p = 0.0252) comparable
to CTGF levels reached by dexamethasone (Fig. 4a).
The combination of dexamethasone and cAMP fur-
ther increased CTGF mRNA expression (26.1 ± 6.6-fold,
p < 0.0001; Fig. 4a). Both forskolin (Fig. 4b) and cilomilast
(Fig. 4c) did not affect basal or dexamethasone-induced
CTGF mRNA levels, and, thus, were not able to
antagonize the stimulatory effect of dexamethasone on
CTGF expression. These results provide strong evidence
that the inhibitory effect of caffeine on glucocorticoid-
induced CTGF expression is not mediated via inhibition
of PDEs. Since caffeine might activate ryanodine receptors
potentially present on H441 cells to release Ca2+, we add-
itionally performed experiments with the ryanodine recep-
tor 1–3 antagonist ruthenium red to inhibit an activation
by caffeine. However, we did not observe any modification
of the inhibitory effect of caffeine when adding ruthenium
red (data not shown).
Impact of dexamethasone and caffeine on TNF-α mRNA
expression and of TNF-α on CTGF mRNA expression in
H441 cells
Since TNF-α has been shown to inhibit CTGF mRNA ex-
pression [56], we treated H441 cells with dexamethasone,
caffeine as well as additional human TNF-α and/or anti-
TNF-α antibody (Fig. 5a). TNF-α significantly reduced
Fig. 2 Treatment with caffeine reduces basal and dexamethasone-
induced CTGF protein expression in IMR-90 cells. IMR-90 cells were
treated with 1 μM dexamethasone and/or 10 mM caffeine for 24 h.
Immunoblotting against CTGF and β-actin was performed as described
in Methods. CTGF levels were normalized to those of β-actin, and
fold differences compared to untreated cells were calculated.
Means + SD of n = 4 independent experiments are shown.
DEX, dexamethasone; *p < 0.05 and ***p < 0.001 compared to
untreated controls; ### p < 0.001 compared to cells treated
with dexamethasone
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dexamethasone-induced CTGF mRNA levels (p < 0.0001).
This effect was antagonized by the addition of anti-TNF-α
antibody (p = 0.0001; Fig. 5a). Therefore, we speculated
that an induction of TNF-α might be responsible for the
observed suppressive effect of caffeine on CTGF mRNA
expression. We analyzed TNF-α mRNA levels in H441
cells treated with dexamethasone alone or in combination
with caffeine. Notably, suppression of CTGF mRNA
induction in H441 cells was inversely correlated with
induced expression of TNF-α mRNA upon treatment with
Fig. 3 Impact of dexamethasone and caffeine on TGF-β1-3 mRNA expression in H441 cells. H441 cells were treated with 1 μM dexamethasone
and/or 10 mM caffeine for 24 h. qPCR against TGF-β1-3 mRNA was performed as described in Methods. TGF-β1 (a), TGF-β2 (b), and TGF-β3 (c)
mRNA levels of H441 cells were normalized to GAPDH, and fold differences compared to untreated cells were calculated. Means + SD of n ≥ 3
independent experiments are shown. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to untreated controls; # p < 0.05 compared to cells treated
with dexamethasone
Fig. 4 Impact of cAMP, forskolin, and cilomilast on CTGF mRNA expression in H441 cells. H441 cells were treated with 1 μM dexamethasone and/
or 10 mM caffeine as well as 1 mM cAMP (a), 10 μM forskolin (b), and 10 μM cilomilast (c) for 24 h. qPCR against CTGF mRNA was performed as
described in Methods. CTGF mRNA levels of H441 cells were normalized to GAPDH, and fold differences compared to untreated cells were
calculated. Means + SD of n ≥ 2 independent experiments are shown. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to untreated controls;
# p < 0.05, ## p < 0.01, and ### p < 0.001 compared to cells treated with dexamethasone; $$$ p < 0.001 compared to cells treated with forskolin;
§§§ p < 0.001 compared to cells treated with cilomilast
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caffeine alone (6.5 ± 2.2-fold, p = 0.0224) or in combin-
ation with dexamethasone (17.3 ± 7.5-fold, p < 0.0001;
Fig. 5b). In accordance with these results, no induction of
TNF-α mRNA was observed after treatment with cAMP
or its combination with dexamethasone (Fig. 5c), indicat-
ing cAMP-independent suppression of CTGF expression
and induction of TNF-α by caffeine. Thus, caffeine might
antagonize glucocorticoid-induced expression of CTGF
via cAMP-independent induction of TNF-α expression.
Caffeine modulates the timely progression of
dexamethasone-induced CTGF mRNA expression
in H441 cells
To reveal, if the observed reduction of glucocorticoid-
mediated CTGF mRNA expression was timely restricted,
we treated H441 cells with dexamethasone and/or caffeine
for various time points. Stimulation with 1 μM dexa-
methasone resulted in significantly induced CTGF mRNA
expression as early as 4 h, slowly further increasing
until 24 h, and still significant after 48 h (6.5 ± 0.3-
fold, p < 0.0001; Fig. 6a). Of note, contrary to our re-
sults at 24 h, caffeine induced CTGF mRNA expres-
sion at 12 h incubation in comparison to untreated
cells (6.0 ± 1.9-fold, p = 0.0262). Simultaneously, parallel
treatment with caffeine and dexamethasone led to a sig-
nificant induction of CTGF mRNA at 8 h (7.7 ± 2.8-fold,
p < 0.0001) and 12 h (13.5 ± 4.0-fold, p < 0.0001), being
more pronounced than with dexamethasone alone. This
induction of CTGF mRNA after the combined treatment
was completely reversed at 24 h and 48 h. In contrast,
after 48 h, levels of CTGF mRNA in cells treated with
caffeine and dexamethasone were even lower than in
untreated cells (0.11 ± 0.02-fold, p = 0.0002). In accord-
ance to the absent CTGF mRNA induction upon co-
stimulation with dexamethasone and caffeine, TNF-α
mRNA expression (Fig. 6b) was significantly induced by
caffeine not before 12 h (2.6 ± 1.0-fold, p = 0.0176), 24 h
(4.8 ± 1.9-fold, p = 0.0181) and 48 h (3.4 ± 0.5-fold, p =
0.0031). This induction was even more pronounced at
24 h and 48 h after the combined treatment of caf-
feine with dexamethasone (8.1 ± 2.7-fold, p = 0.0002
and 9.5 ± 1.2-fold, p < 0.0001, respectively).
Discussion
Our data reveal increased expression of CTGF in differ-
ent lung cell lines by glucocorticoids. Our findings are in
accordance with previous studies documenting
glucocorticoid-induced expression of CTGF in various
cell types [57–63]. If glucocorticoids may have adverse
effects on airway remodeling processes via modification
of pulmonary CTGF expression in vivo has yet to be de-
fined. Although a short-term benefit of glucocorticoid
treatment in severe forms of BPD has been sufficiently
documented [64], concerns regarding significant un-
favorable effects, including adverse neurological out-
come, remain [65, 66]. Our data may add additional
Fig. 5 Impact of TNF-α, dexamethasone, caffeine, and cAMP on H441 CTGF and TNF-α mRNA expression. H441 cells were treated with 1 μM
dexamethasone, 10 mM caffeine, 1 mM cAMP, 10 ng/mL recombinant TNF-α, and/or 5 μg/mL anti-human TNF-α antibody for 24 h. qPCR against
TNF-α and CTGF mRNA were performed as described in Methods. CTGF (a) and TNF-α (b, c) mRNA levels of H441 cells were normalized to
GAPDH, and fold differences compared to untreated cells were calculated. Means + SD of n≥ 3 independent experiments are shown. αTNF-α,
anti-TNF-α antibody; *p < 0.05 and ***p < 0.001 compared to untreated controls; # p < 0.05 and ### p < 0.001 compared to cells treated with
dexamethasone; $$$ p < 0.001 compared to cells treated with TNF-α; §§§ p < 0.001 compared to cells treated with TNF-α and dexamethasone;
††† p < 0.001 compared to cells treated with caffeine
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concerns in terms of glucocorticoid-related long-term
impairments [34].
We observed induction of CTGF by different gluco-
corticoids on the transcriptional level in lung epithelial
cell and fetal lung fibroblast models as well as on the
translational level in the latter. Notably, these findings
were not restricted to dexamethasone and betametha-
sone but were also confirmed for budesonide, prednisol-
one and hydrocortisone, often being considered to cause
less side effects regarding treatment strategies in BPD
[33, 67–70].
To the best of our knowledge, this is the first study to
describe a glucocorticoid-induced expression of CTGF
in human lung derived epithelial cells as well as fetal
lung fibroblasts. These findings may be of considerable
relevance, pointing to potential pro-fibrotic, CTGF-
related adverse effects of glucocorticoids on lung devel-
opment and tissue remodeling.
It has been suggested that inhibition of CTGF can
prevent and reverse the process of fibrosis [26]. Com-
bining pharmacological prophylaxis or treatment of
CTGF-related pro-fibrotic lung injury with current
therapies for inflammatory lung diseases may over-
come current limitations of the latter [12]. In our set-
ting, glucocorticoid-induced mRNA and protein
expression of CTGF was attenuated by simultaneous
exposure of lung epithelial cells and fetal lung fibro-
blasts to caffeine for 24 h and 48 h, respectively.
Caffeine, already frequently used to reduce apnea of
prematurity [40], has been ascribed to preventive
effects on the development of BPD [71, 72]. In ac-
cordance to these clinical observations, our data point
to the ability of caffeine to significantly suppress
long-term glucocorticoid-induced CTGF expression
on the transcriptional and translational level by modi-
fying its timely progression. Moreover, caffeine may
even reduce basal expression levels of CTGF.
Since highest levels of CTGF mRNA-induction by
dexamethasone were detected in H441 cells, we focused
on this cell line to identify the underlying molecular
mechanisms of the stimulatory ability of glucocorticoids
and the reductive ability of caffeine. We observed an in-
duction of TGF-β2 and TGF-β3 mRNA by dexametha-
sone rather than of TGF-β1. Although TGF-β1 has been
considered to be the predominant and most potent iso-
form in terms of CTGF induction [29], we hypothesize
that glucocorticoid-induced expression of CTGF is likely
to be independent of TGF-β1 in lung epithelial cells. In
accordance to our data, TGF-β1-independent induction
of CTGF expression has also been observed in cultured
mouse fibroblasts as well as murine heart, kidney, and
skin tissue [57]. The slight induction of TGF-β2 mRNA
was no longer present after the addition of caffeine,
indicating that TGF-β2 might be, at least in part, in-
volved in the observed glucocorticoid-mediated induc-
tion of CTGF. Surprisingly, the induction of TGF-β3
was also observed for the treatment with caffeine to
even higher amounts than by dexamethasone, indicating
that alternative pathways are involved in the induction
of CTGF. Although an induction of CTGF gene expres-
sion has also been described for TGF-β3 in fibroblasts
[73], this TGF-β isoform has been ascribed to more posi-
tive effects in terms of pulmonary fibrosis than TGF-β1
[74] and even anti-scarring abilities have been assumed
for TGF-β3 [75]. The observed induction of TGF-β3
mRNA might therefore point to a more anti-fibrotic abil-
ity of caffeine counteracting TGF-β1’s pro-fibrotic role.
Analyzing potential underlying mechanisms, we found
the reduction of glucocorticoid-mediated CTGF expres-
sion by caffeine independent of PDE-inhibition, since
treatment with cAMP or the adenylyl cyclase activator
forskolin and the PDE4-specific inhibitor cilomilast
showed no inhibitory effects. These results differ from
those published for fibroblasts showing downregulation
Fig. 6 Treatment with caffeine modulates timely progression of dexamethasone-induced CTGF mRNA expression in H441 cells. H441 cells were
treated with 1 μM dexamethasone and/or 10 mM caffeine for different time points as indicated. CTGF (a) and TNF-α (b) mRNA levels of H441 cells
were normalized to GAPDH, and fold differences compared to untreated cells were calculated for each time point. Means + SD of n = 4 experiments
are shown. *p < 0.05, **p < 0.01, and ***p < 0.001 increased mRNA expression compared to untreated controls
Fehrholz et al. Respiratory Research  (2017) 18:51 Page 8 of 11
of TGF-β1-mediated CTGF expression via increased
cAMP levels [76]. Accordingly, neither TGF-β1 and
TGF-β3 signaling, nor the accumulation of cAMP seems
to be the molecular basis for the inhibition of the
glucocorticoid-mediated induction of CTGF by caffeine
reported here. Although caffeine is able to increase the
sensitivity of ryanodine receptors to cytosolic Ca2+ of
airway smooth muscle cells [77], our experiments indi-
cate that Ca2+ release by caffeine-mediated activation of
ryanodine receptors is most likely not involved in the
observed modifications of CTGF mRNA expression in
lung epithelial cells. A further potential mechanism of
caffeine is to act on bitter taste receptors, which have re-
cently been identified in bronchial epithelial cells [78]. If
these receptors are also expressed on lung epithelial cells
or fibroblasts and may interact with the CTGF/TGF-β
network has to be further elucidated.
Another possibility of caffeine’s mechanism of action
regarding the observed downregulation of CTGF expres-
sion could be a potential impact on TNF-α which has
been described as an inhibitor of CTGF expression [56].
Although TNF-α is a prototypic pro-inflammatory cyto-
kine, its pleiotropic effects may often lead to opposing
outcomes during the development of immune-mediated
diseases [79]. We observed a significant increase of
TNF-α mRNA by exposure of lung epithelial cells to caf-
feine and an inhibition of dexamethasone-induced
CTGF expression by exogenous TNF-α. This is in con-
trast to studies reporting a reduction of TNF-α expres-
sion via nonselective PDE inhibition in monocytes,
lymphocytes, and whole blood at lower caffeine concen-
trations [80–82]. The promoter of TNF-α contains a
cAMP response element [83] and we found an induction
of CTGF mRNA by cAMP which could have subse-
quently been provoked via caffeine-mediated increase of
cAMP [53]. Thus, one may speculate that caffeine might
have also induced TNF-α mRNA expression via cAMP
in our setting, although we still observed unmodified
TNF-α mRNA levels after exogenous cAMP, which is
again questioning this assumption.
We may further attribute the caffeine-mediated
induction of CTGF expression, observed at very early
time points, to caffeine-mediated increases in
cytosolic cAMP [53]. Moreover, an indirect induction
of short-lived CTGF mRNA-degrading proteins by
caffeine in consequence of this initial induction could
be jointly responsible for the long-term reduction of
CTGF. Such short-lived proteins have been suggested
to be induced after upregulation of CTGF mRNA to
prevent uncontrolled CTGF expression [14]. As far as
cAMP is concerned, it is possible that its early rising
levels provoked by caffeine [53] mediated an induc-
tion of CTGF mRNA which may be later antagonized
by TNF-α.
There are some limitations of this study to be considered.
Although CTGF may play a crucial role in development of
lung fibrosis, it is likely to represent only one fraction of a
much bigger network of regulating factors inducing fibrotic
diseases which also need to be examined. Moreover,
caffeine-induced suppression of CTGF expression was only
observed at high in vitro concentrations of caffeine, possibly
not reflecting physiologic conditions. Future studies will in-
clude investigations of primary cells to gain further insights
into potential pro- and anti-fibrotic features of glucocorti-
coids and methylxanthines and the impact of co-
medication. Concerning potential pro-fibrotic effects of
glucocorticoids, their long-term usage should be carefully
considered especially in preterm neonates. However, ad-
verse pro-fibrotic effects may be attenuated by simultan-
eous and long-term administration of caffeine.
Conclusions
To the best of our knowledge, this is the first study to
describe a glucocorticoid-induced expression of CTGF in
human lung derived cells. Our data may be of consider-
able relevance as they point to potential pro-fibrotic,
CTGF-related adverse effects of glucocorticoids on lung
development and tissue remodeling. Although attenuating
preterm lung inflammation in the short run, application of
glucocorticoids might negatively affect airway remodeling
via induction of CTGF in the long term. The underlying
mechanisms seem to be independent of TGF-β1. Thus,
glucocorticoid treatment may be carefully considered in
chronic inflammatory lung diseases, such as BPD in pre-
term infants. According to our data, a co-medication with
caffeine may abrogate long-term glucocorticoid-induced
CTGF expression and, therefore, help to attenuate the
progression of BPD.
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